Absci Prices $100M Offering at 26.5% Discount; Eli Lilly Invests $40M

summarizeSummary

Absci Corp announced the pricing of a $100 million underwritten public offering at a 26.5% discount, with Eli Lilly & Co. investing $40 million alongside other institutional investors.

check_boxKey Events

• Underwritten Public Offering Priced

  Absci Corp entered into an underwriting agreement to sell 13,495,277 shares of common stock, expecting gross proceeds of approximately $100 million and net proceeds of $93.5 million.

• Significant Discounted Pricing

  The shares are being sold at an offering price of $7.41 per share, representing a 26.5% discount compared to the current stock price of $10.08.

• Strategic Investor Participation

  The offering includes a $40 million investment from Eli Lilly & Co., along with participation from other leading financial institutions such as Adage, BVF Partners, Columbia Threadneedle, Invus, and Redmile.

• Use of Proceeds for ABS-201 Advancement

  Net proceeds will primarily fund the advancement of ABS-201, the company's AI-designed anti-PRLR antibody product candidate, across androgenetic alopecia and endometriosis, and for general corporate purposes.

auto_awesomeAnalysis

Absci Corp has priced a significant $100 million underwritten public offering at a substantial discount to its current market price. While the 26.5% discount and resulting dilution are negative for existing shareholders, the offering is bolstered by a $40 million investment from Eli Lilly & Co. and participation from other leading institutional investors. This strategic backing, especially following recent positive Phase 1 data for its lead drug candidate ABS-201, provides crucial funding for the advancement of this key pipeline asset and extends the company's operational runway.